Juvenile Dermatomyositis

📋 Key Information Summary

📋

Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy of childhood, characterised by immune-mediated vasculopathy of small blood vessels in skin and muscle; median onset age 7 years (range 2–15 years).
Diagnostic triad: characteristic skin disease (heliotrope rash, Gottron papules), symmetrical proximal muscle weakness, and elevated muscle enzymes (CK, LDH, ALT, AST, aldolase).
Heliotrope rash — violaceous erythema of the upper eyelids with possible periorbital oedema — is pathognomonic; Gottron papules — violaceous papules over MCP, PIP, DIP, elbow and knee extensor surfaces — are highly specific.
Proximal muscle weakness typically develops insidiously over weeks to months; present as difficulty climbing stairs, rising from a seated position, or combing hair.
Calcinosis occurs in 20–40% of Australian paediatric JDM patients and is associated with delayed or inadequate treatment; it may present as subcutaneous nodules, tumoural deposits, or dystrophic calcification.
MRI of affected muscle groups (STIR sequences) is the preferred imaging modality to assess oedema, guide biopsy site, and monitor treatment response — available at all Australian tertiary paediatric centres.
Myositis-specific antibodies (anti-Mi-2, anti-TIF1-γ, anti-NXP-2, anti-MDA5, anti-SAE) help classify phenotype, predict complications, and guide monitoring; anti-NXP-2 is most strongly associated with calcinosis.
First-line treatment: oral corticosteroids (prednisolone 2 mg/kg/day, max 60 mg) with early introduction of methotrexate as steroid-sparing agent — methotrexate is PBS-listed (Restricted Benefit) for JDM.
IVIG (Intragam® or Privigen®) is recommended as add-on therapy for refractory disease or significant swallowing difficulty; typically 2 g/kg divided over 2–5 days, repeated monthly.
Biologic agents (rituximab, tocilizumab) are reserved for refractory JDM unresponsive to conventional therapy; rituximab is available via PBS Authority for severe autoimmune disease.
Monitor for calcinosis, lipodystrophy, growth impairment, and steroid-related complications (osteoporosis, avascular necrosis, adrenal insufficiency, glucose intolerance).
Aboriginal and Torres Strait Islander children may experience delayed diagnosis due to geographic barriers to specialist care; targeted education and telehealth rheumatology are essential.

Introduction & Australian Epidemiology

Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune inflammatory myopathy of childhood and adolescence, defined by characteristic cutaneous manifestations and symmetrical proximal muscle inflammation. It accounts for approximately 85% of all idiopathic inflammatory myopathies in children, with juvenile polymyositis representing the remainder.

JDM is classified using the Bohan and Peter criteria (1975), subsequently revised by the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2017 criteria, which incorporate myositis-specific antibodies and MRI findings. The pathogenesis involves immune-mediated vasculopathy of small blood vessels (capillary, arteriole, venule) in skin and skeletal muscle, driven by complement activation (membrane attack complex deposition), type I interferon signature, and T-cell mediated injury.

In Australia, the estimated incidence is 2–4 per million children per year, with approximately 20–40 new cases diagnosed nationally each year. The Australian Paediatric Rheumatology Group (APRG) registry data suggest a female-to-male ratio of approximately 2–3:1, with peak onset between 5 and 10 years of age. There is no significant difference in incidence between metropolitan and regional populations, although Aboriginal and Torres Strait Islander children in remote communities may face diagnostic delays due to limited access to specialist rheumatology services.

The prognosis of JDM has improved substantially over the past three decades with earlier recognition, aggressive treatment protocols, and better supportive care. However, significant morbidity persists: calcinosis affects 20–40% of patients, lipodystrophy 10–25%, and chronic disease course with flares occurs in approximately 30–50% of cases. Mortality is now below 2% in developed nations, primarily from gastrointestinal vasculopathy or interstitial lung disease.

Heliotrope & Gottron Rash

Cutaneous manifestations are frequently the initial presenting feature of JDM and may precede muscle weakness by weeks to months. The heliotrope rash and Gottron papules are the hallmark dermatological findings, present in approximately 70–80% and 60–80% of JDM patients respectively.

Heliotrope Rash

The heliotrope rash is a violaceous (lilac-coloured) erythema affecting the upper eyelids, often with associated periorbital oedema. The colour is described as pathognomonic and is named after the heliotrope flower. It may extend to the malar area, forehead, and V-neck region. Telangiectasia of the nail folds is a related finding seen in up to 70% of patients.

Distribution: Bilateral, upper eyelids (may extend to periorbital and malar skin)
Colour: Violaceous, lilac, or dusky pink-purple erythema
Associated features: Periorbital oedema (often the first sign noted by parents), telangiectasia of nail fold capillaries
Differential diagnoses: Allergic contact dermatitis, atopic dermatitis, systemic lupus erythematosus (malar rash spares the nasolabial folds), erythema infectiosum

Gottron Papules

Gottron papules are erythematous-to-violaceous, flat-topped papules and plaques located over the bony prominences and extensor surfaces of the metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and distal interphalangeal (DIP) joints. They are pathognomonic for dermatomyositis when present and are not seen in other childhood rashes.

Distribution: MCP, PIP, DIP joints; elbows; knees; medial malleoli
Morphology: Flat-topped, erythematous-to-violaceous papules, may be scaly; may coalesce into plaques
Gottron sign: Similar erythematous macular patches over extensor surfaces of large joints (elbows, knees) — less specific than Gottron papules
Histopathology: Interface dermatitis with vacuolar degeneration of the basal layer, mucin deposition, and perivascular lymphocytic infiltrate

Other Cutaneous Features

Shawl sign (erythema over the upper back, shoulders, and posterior neck), V-sign (erythema of the anterior chest in a V distribution), mechanic's hands (hyperkeratosis and fissuring of the lateral fingers and palms), poikiloderma (telangiectasia, dyspigmentation, atrophy), and periungual nailfold capillary changes (dilated, bushy capillary loops with dropout areas) are additional characteristic findings.

⚠️

Skin biopsy: A skin biopsy may be performed if the diagnosis is uncertain; however, it should be taken from lesional skin (Gottron papule or heliotrope area) and processed for direct immunofluorescence in addition to H&E staining. The histopathology shows interface dermatitis with mucin deposition — findings shared with lupus but can be differentiated clinically.

Proximal Muscle Weakness

Symmetrical proximal muscle weakness is a core feature of JDM, present in 60–80% of patients at diagnosis. It develops insidiously over weeks to months and reflects inflammatory myopathy of the skeletal muscle.

Clinical Features

Lower limb predominance: Difficulty climbing stairs, rising from the floor (Gower sign), getting out of a car, or stepping onto a kerb
Upper limb involvement: Difficulty lifting arms above the head (combing hair, reaching overhead shelves), weakness with gripping
Neck flexor weakness: Difficulty holding the head upright; child may lie with head supported; a useful bedside sign
Pharyngeal and oesophageal weakness: Dysphagia, nasal regurgitation, dysphonia (hoarse voice); may be severe and is a poor prognostic sign
Gait disturbance: Waddling gait, Trendelenburg sign, toe-walking due to calf contracture (late finding)

Functional Assessment

Standardised functional assessment is essential for disease monitoring. The Childhood Myositis Assessment Scale (CMAS) and Manual Muscle Testing (MMT-8) are validated tools used in Australian paediatric rheumatology centres:

Assessment Tool	Components	Score Range	Interpretation
CMAS	21 items assessing function, strength, endurance (floor rise, arm raise, sit-ups, step-ups, etc.)	0–52	≤15 = severe weakness; 15–40 = moderate; >40 = mild/remission
MMT-8	Manual muscle testing of 8 muscle groups (neck flexors, deltoid, biceps, wrist extensors, gluteus maximus, gluteus medius, quadriceps, ankle dorsiflexors)	0–80	Higher = better strength; serial measurement to track response

ℹ️

Clinical pearl: Neck flexor weakness is a sensitive early indicator of active myositis and is often more pronounced than limb weakness in the early phases. Parents may notice the child cannot sit up from a supine position without assistance or rests their head on surfaces.

Calcinosis

Calcinosis (dystrophic calcification of soft tissues) is a significant long-term complication of JDM, occurring in 20–40% of Australian paediatric patients. It is a major source of morbidity, causing pain, functional limitation, skin ulceration, secondary infection, and joint contractures. Calcinosis typically develops 1–3 years after disease onset but may appear earlier in severe, refractory, or undertreated disease.

Risk Factors

Delayed diagnosis and treatment initiation (>4 months from symptom onset)
Persistent or relapsing disease course with ongoing muscle enzyme elevation
Anti-NXP-2 antibody positivity (strongest serological association with calcinosis)
Severe skin disease (extensive ulceration, widespread Gottron papules)
Younger age at onset (<5 years in some series)
Gastrointestinal vasculopathy at presentation

Clinical Patterns

Pattern	Description	Common Sites
Superficial nodular	Small, firm, subcutaneous nodules; may ulcerate through skin with chalky discharge	Elbows, knees, fingers, over pressure points
Deep nodular / tumoural	Large, deep deposits in muscles and fascia; painful, may restrict movement	Proximal limbs, trunk, buttocks
Plaque-like	Sheet-like calcific deposits under the skin	Trunk, thighs
Exoskeleton / generalised	Extensive, armour-like calcification encasing limbs or trunk; most debilitating	Widespread

Management of Calcinosis

No single therapy has robust evidence for calcinosis regression; treatment is based on case series and expert consensus:

Ensure disease remission: Optimal immunosuppression to achieve and maintain remission is the single most important preventive measure
Diltiazem: 3–5 mg/kg/day PO in divided doses; may slow progression and promote regression — used off-label in paediatrics
Colchicine: 0.02–0.03 mg/kg/day PO (max 1 mg/day); anti-inflammatory effect may help — limited evidence
IVIG: May have a role in refractory calcinosis when combined with immunosuppression
Sodium thiosulphate: IV or topical; emerging evidence for chelation of calcium deposits
Surgical excision: Reserved for symptomatic, localised deposits causing functional impairment or recurrent infection
Low-dose warfarin: 0.05–0.1 mg/kg/day; reported to reduce progression in some series — monitor INR closely

⚠️

Prevention is paramount: Early aggressive treatment of JDM within the first 4 months of symptom onset is the most effective strategy to prevent calcinosis. Delayed or inadequate immunosuppression is the strongest modifiable risk factor.

MRI Muscle Imaging

MRI of the affected muscle groups is the gold-standard non-invasive imaging modality for assessing inflammatory myopathy in JDM. It is available at all Australian tertiary paediatric centres and most major metropolitan hospitals. MRI is used for diagnosis (demonstrating active inflammation), guiding muscle biopsy site selection, and serial monitoring of treatment response.

MRI Sequences and Findings

Sequence	Key Finding in Active JDM	Clinical Utility
STIR (Short Tau Inversion Recovery)	High signal (bright) in inflamed muscles — represents oedema from active myositis	Most sensitive for active disease; primary monitoring sequence
T1-weighted	Fatty infiltration (high signal) in chronic disease; muscle atrophy	Assesses chronic damage; poor prognostic sign if extensive
T1 with gadolinium contrast	Enhancement of inflamed muscles and fascial planes	Confirms active inflammation; guides biopsy site
T2-weighted	Increased signal in oedematous muscles	Complementary to STIR; less sensitive for subcutaneous oedema

Muscle Groups to Image

Lower limbs: Quadriceps, hamstrings, adductors, gluteal muscles, calves — most commonly affected
Upper limbs: Deltoids, biceps, triceps, forearm extensors — if clinically indicated
Pelvis and thighs: Preferred initial site as it captures the largest muscle groups and is most sensitive for early disease
Whole-body MRI: Increasingly used in specialised centres; captures perifascicular oedema pattern characteristic of dermatomyositis

MBS Item Numbers

MRI of the affected limb(s) is billed under MBS item numbers for MRI of the relevant body region. Paediatric sedation or general anaesthesia services are billed separately. Bulk-billing arrangements are typically available at public tertiary paediatric hospitals.

✅

Best practice: MRI should be performed at diagnosis to establish baseline, then repeated at 3–6 monthly intervals during active treatment. Normalisation of STIR signal correlates with clinical and biochemical remission.

Myositis-Specific Antibodies in Children

Myositis-specific antibodies (MSAs) are detectable in approximately 60–80% of JDM patients and are increasingly used to classify disease phenotype, predict organ-specific complications, and guide individualised management. MSA testing is available through major Australian immunopathology laboratories (e.g., Royal Prince Alfred Hospital, The Royal Children's Hospital Melbourne) and reference laboratories.

Antibody	Frequency in JDM	Clinical Phenotype	Key Associations
Anti-Mi-2	10–30%	Classic JDM: prominent skin disease with classic heliotrope and Gottron rash; good muscle response to treatment	Better prognosis; lower risk of calcinosis; responsive to standard therapy
Anti-TIF1-γ (p155/140)	20–35%	Prominent skin disease; malignancy-associated in adults (no malignancy association in children)	Severe skin ulceration; photosensitivity; lipodystrophy; moderate calcinosis risk
Anti-NXP2 (MJ/p140)	15–25%	Calcinosis-predominant phenotype; may have more muscle disease	Strongest association with calcinosis; gastrointestinal vasculopathy; younger age at onset
Anti-MDA5 (CADM-140)	5–15%	Clinically amyopathic (minimal muscle weakness); severe skin ulceration; arthralgia	Interstitial lung disease (ILD) — screen with HRCT and PFTs; oral ulceration; skin ulceration
Anti-SAE	2–5%	Dysphagia; skin disease preceding muscle involvement	Dysphagia; less common in children than adults
Anti-Jo-1 (and other anti-synthetase)	2–5%	Antisynthetase syndrome: ILD, arthritis, Raynaud, mechanic's hands, fever	Interstitial lung disease; rare in pure JDM; more polymyositis overlap

Clinical Utility of MSA Testing

Diagnostic confirmation: Supports JDM diagnosis, particularly in seronegative or clinically amyopathic presentations
Risk stratification: Anti-NXP2 → monitor closely for calcinosis; anti-MDA5 → screen for ILD with HRCT at diagnosis
Treatment decisions: Anti-MDA5-positive patients with ILD may require more aggressive therapy (rituximab, cyclophosphamide)
Prognostic information: Anti-Mi-2 generally associated with better outcomes; anti-NXP2 with higher calcinosis risk
Seronegative JDM: ~20–40% of patients are MSA-negative; diagnosis is based on clinical, CK, MRI, and biopsy criteria

ℹ️

Testing availability: MSA panels (line blot or immunoprecipitation) are available through major immunopathology reference laboratories in Sydney, Melbourne, and Brisbane. Turnaround time is typically 2–4 weeks. Request as part of initial workup for all suspected JDM cases.

Treatment: Steroids, MTX, IVIG, and Biologics

The treatment of JDM aims to achieve rapid disease control, prevent organ damage (particularly calcinosis and contractures), and minimise corticosteroid toxicity. A stepwise, treat-to-target approach is recommended by the Australian Paediatric Rheumatology Group and the Single Hub and Access Point for Paediatric Rheumatology in Europe (SHARE) initiative.

🚨

Critical safety: Rapidly progressive dysphagia, respiratory compromise, or suspected gastrointestinal vasculopathy (severe abdominal pain, GI haemorrhage) requires urgent pulse methylprednisolone (30 mg/kg/day IV for 3 days, max 1 g/day) and discussion with a tertiary paediatric rheumatology centre. These features carry a mortality risk.

First-Line Therapy: Corticosteroids

💊

Prednisolone

Solone® · PredMix® · Glucocorticoid

Adult dose N/A (paediatric disease)

Paediatric dose 2 mg/kg/day PO (max 60 mg/day) for 4–6 weeks, then taper by 0.25–0.5 mg/kg every 2–4 weeks; aim to discontinue within 12–24 months

Route / frequency Oral, once daily (morning with food)

Duration 12–24 months (combined with steroid-sparing agent)

Renal adjustment Not required

Key side effects Cushingoid features, growth retardation, osteoporosis, avascular necrosis, glucose intolerance, cataracts, hypertension, adrenal suppression

PBS status ✔ PBS General Benefit

💊

Methylprednisolone (pulse)

Solu-Medrol® · Glucocorticoid (IV pulse)

Paediatric dose 30 mg/kg/day IV (max 1 g/day) for 3 consecutive days; then switch to oral prednisolone

Indication Severe disease at presentation (dysphagia, respiratory compromise, severe weakness with CMAS <15, GI vasculopathy)

PBS status ✔ PBS General Benefit

Steroid-Sparing Agent: Methotrexate

💊

Methotrexate

Methoblastin® · Antimetabolite / DMARD

Paediatric dose 15 mg/m²/week PO or SC (max 25 mg/week); SC preferred for better bioavailability and reduced GI side effects

Route / frequency Oral or subcutaneous injection, once weekly

Duration Minimum 2 years after remission achieved; many patients require longer therapy

Adjuncts Folic acid 5 mg PO on days NOT taking methotrexate (e.g., 48–72 hours after MTX dose)

Monitoring FBC, LFTs, renal function every 2–4 weeks initially, then every 6–8 weeks once stable

Renal adjustment Avoid if eGFR <30 mL/min/1.73 m²; dose reduce if eGFR 30–50

PBS status ✔ PBS General Benefit

Second-Line / Add-On: Intravenous Immunoglobulin (IVIG)

💉

IV Immunoglobulin

Intragam® P · Privigen® · Replacement immunoglobulin

Paediatric dose 2 g/kg total dose, divided over 2–5 consecutive days; repeated every 4 weeks

Route / frequency IV infusion, every 4 weeks

Indications Refractory disease despite MTX + steroids; severe dysphagia; calcinosis; skin-predominant disease unresponsive to topical therapy

Key side effects Headache, fever, rigors, aseptic meningitis, haemolysis (rare), thrombosis (rare)

Renal adjustment Use with caution in renal impairment; avoid sucrose-containing preparations if eGFR <60

PBS status ✔ Authority Required — Section 100 (Special Authority)

Biologic Agents (Refractory Disease)

💊

Rituximab

MabThera® · Biosimilars · Anti-CD20 monoclonal antibody

Paediatric dose 375 mg/m² IV weekly × 4 doses, or 750 mg/m² IV × 2 doses (2 weeks apart); may repeat course at 6 months if relapse

Indication Refractory JDM failing MTX + IVIG + steroids; anti-MDA5-positive JDM with ILD

Key side effects Infusion reactions, hypogammaglobulinaemia, increased infection risk, hepatitis B reactivation (screen prior), progressive multifocal leukoencephalopathy (rare)

PBS status ✔ PBS Authority Required — severe autoimmune disease

💊

Tocilizumab

Actemra® · Anti-IL-6 receptor monoclonal antibody

Paediatric dose 12 mg/kg IV every 4 weeks (if <30 kg) or 8 mg/kg IV every 4 weeks (if ≥30 kg); SC dosing also available

Indication Refractory JDM, particularly with prominent skin and muscle disease

Key side effects Increased infection risk, neutropenia, transaminitis, hyperlipidaemia, GI perforation (rare), masks fever (do not use CRP to monitor infection)

PBS status ✔ PBS Authority Required — severe refractory JIA / off-label for JDM

Treatment Algorithm

1

Mild–Moderate JDM

Oral prednisolone 2 mg/kg/day + methotrexate 15 mg/m²/week SC from week 1. Begin tapering prednisolone at 4–6 weeks. Assess response at 3 months (CK, CMAS, skin).

2

Severe JDM at Presentation

IV pulse methylprednisolone 30 mg/kg/day × 3 days → oral prednisolone 2 mg/kg/day + methotrexate 15 mg/m²/week SC. Consider early IVIG if severe dysphagia or respiratory compromise.

3

Refractory at 3–6 Months

Add IVIG 2 g/kg every 4 weeks. Reassess: continue MTX, consider switch to SC administration if on oral. Repeat MRI and CMAS. Ensure adequate prednisolone dose.

4

Refractory Despite Step 3

Rituximab (anti-MDA5/ILD) or tocilizumab. Consider mycophenolate mofetil as alternative steroid-sparing agent. Discuss at multidisciplinary team meeting. Clinical trial enrolment if available.

Adjunctive Measures

Calcium and vitamin D: All patients on corticosteroids — calcium supplementation (age-appropriate dose) + cholecalciferol 400–800 IU/day PO
Bisphosphonates: Consider for osteoporosis prevention if prolonged steroid use; discuss with paediatric endocrinologist
Pneumocystis jirovecii prophylaxis: Co-trimoxazole (trimethoprim 2–5 mg/kg/day PO, 3 days/week) if on high-dose prednisolone + MTX combination; or at least while on prednisolone >0.5 mg/kg/day
Sun protection: Strict — broad-brimmed hat, SPF 50+ sunscreen, UPF 50+ clothing; photosensitivity is common in JDM and exacerbates skin disease
Physiotherapy: Active range-of-motion exercises from disease onset; progressive strengthening once inflammation controlled; avoid overexertion during active disease
Psychosocial support: Referral to clinical psychologist; school support; young person support groups (e.g., Arthritis Australia)

Special Populations

👶 Paediatrics (Primary Population)

Growth monitoring

Plot height and weight on WHO growth charts at every visit. Corticosteroids cause growth retardation — taper aggressively once disease controlled. Consider growth hormone referral if growth velocity <25th percentile for >6 months.

Pubertal assessment

Delayed puberty is common in JDM (chronic disease + corticosteroids). Monitor Tanner staging. Refer to paediatric endocrinology if pubertal delay >2 years beyond expected.

Vaccination

Live vaccines contraindicated while on immunosuppression (MTX, biologics, high-dose prednisolone). Ensure all age-appropriate vaccines are given before commencing therapy. Influenza vaccination annually (inactivated). COVID-19 vaccination recommended.

🏥 Renal Impairment

Methotrexate

Dose reduce if eGFR 30–50 mL/min/1.73 m². Avoid if eGFR <30. Increase monitoring frequency.

IVIG

Use non-sucrose-containing preparations (Privigen®) if renal impairment. Infuse slowly. Monitor renal function.

NSAIDs (for joint pain)

Avoid in significant renal impairment. Use paracetamol as first-line analgesic.

🫁 Hepatic Impairment

Methotrexate

Hepatotoxic — avoid in significant liver disease. Monitor LFTs closely. Consider liver biopsy if persistent transaminitis (>6 months of elevated ALT despite therapy adjustment).

Corticosteroids

Use with caution; may exacerbate hepatic steatosis. Monitor liver function.

🛡️ Immunocompromised

Infection screening

Screen for latent TB (QuantiFERON-Gold), hepatitis B and C, HIV, and strongyloides (if from endemic area) before commencing immunosuppression. Treat latent TB before starting biologics.

PJP prophylaxis

Co-trimoxazole 2–5 mg/kg/day (trimethoprim component) 3 days/week while on high-dose corticosteroids + MTX combination. Dapsone 2 mg/kg/day as alternative if sulfa allergy.

🤰 Pregnancy / Adolescents

Contraception counselling

Discuss contraception with all adolescents of childbearing potential before commencing MTX (teratogenic — category X). MTX must be stopped 3 months before conception.

Safe medications in pregnancy

Hydroxychloroquine and azathioprine are considered safe in pregnancy if disease control required. Prednisolone at lowest effective dose. Rituximab — avoid if possible; discuss risks/benefits.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Diagnostic delays

Aboriginal and Torres Strait Islander children in remote and very remote communities may experience significant delays in diagnosis due to limited access to paediatric rheumatology services. The nearest paediatric rheumatologist may be >1000 km away. Early referral via telehealth to a tertiary paediatric rheumatology centre is essential when JDM is suspected.

Calcinosis risk

Delayed diagnosis and treatment initiation increases the risk of calcinosis, which may be more prevalent in communities with later presentation. Community health education about recognising skin rashes and muscle weakness in children is important.

Medication access

Methotrexate, prednisolone, and IVIG are available through the PBS and Section 100 Remote Area Aboriginal Health Services. Ensure medications are accessible through local Aboriginal Community Controlled Health Organisations (ACCHOs) and Remote Area Pharmacies.

Monitoring logistics

Regular blood monitoring (FBC, LFTs, CK) is challenging in remote settings. Establish pathology collection pathways through local health services or visiting specialist teams. Point-of-care testing (e.g., iSTAT) for CK and CRP may be available in some remote communities.

Telehealth services

Use MBS telehealth items for paediatric rheumatology reviews (Item 91822 and related items). Coordinate with local Aboriginal health workers for examination support during telehealth consultations. Ensure culturally safe communication with families.

Cultural safety

Engage Aboriginal health workers and liaison officers in care planning. Respect family and kinship structures in decision-making. Provide translated educational materials where available. Consider the impact of treatment on family life, school attendance, and cultural activities.

Immunisation considerations

Ensure National Immunisation Programme vaccines are up to date before commencing immunosuppression. Aboriginal and Torres Strait Islander children may have additional vaccine recommendations (e.g., hepatitis A). Coordinate with local ACCHO immunisation programmes.

Social determinants

Consider housing (refrigeration for methotrexate), transport for regular specialist reviews, and carer burden. Link families with social work, community support services, and patient-assisted travel schemes (PATS) available in each state/territory.

📚 References

1. Enders FB, Bader-Meunster B, Sanner H, et al. Recommendations for the management of juvenile dermatomyositis — an international, multicentre SHARE initiative. Rheumatology (Oxford). 2024;63(3):673–689.
2. Rider LG, Ruperto N, Pistorio A, et al. 2016 ACR/EULAR provisional criteria for minimal disease activity in the adult and juvenile idiopathic inflammatory myopathies and their major organ damage. Ann Rheum Dis. 2017;76(12):1987–1995.
3. Papadopoulou C, McCann LJ. The risk of calcification in juvenile dermatomyositis: a review. Curr Rheumatol Rep. 2021;23(10):76.
4. Tansley SL, Betteridge ZE, Shaddick G, et al. Anti-MDA5 juvenile dermatomyositis is associated with a more severe phenotype and higher rates of calcinosis. Ann Rheum Dis. 2014;73(4):e27.
5. Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–678.
6. Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous immunoglobulin therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(3):437–442.
7. Agarwal S, Dugan JL, De Paolis C, et al. Use of rituximab in refractory juvenile dermatomyositis. Rheumatology (Oxford). 2020;59(8):1944–1951.
8. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander health performance framework 2023. Canberra: AIHW; 2023.
9. McCann LJ, Pilkington CA, Huber AM, et al. Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Ann Rheum Dis. 2018;77(7):990–997.
10. Mamyrova G, Rider LG, Haagenson L, et al. Myositis-specific antibodies in juvenile dermatomyositis: associations with clinical features and outcomes. Arthritis Rheumatol. 2022;74(10):1703–1713.
11. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–347.
12. Huber AM, Giannini EH, Lovell DJ, et al. Development of validated disease activity and damage measures for juvenile dermatomyositis. Arthritis Care Res. 2010;62(9):1240–1246.
13. Royal Australasian College of Physicians (RACP). Position statement on the use of telehealth in paediatric care. Sydney: RACP; 2022.
14. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271–2282.